Characterisation of alloantigens and their cognate T cell responses in Acute Myeloid Leukaemia. Implications For A Novel Approach To TCR Therapy

OxTalks is Changing

During Michaelmas Term, OxTalks will be moving to a new platform (full details are available on the Staff Gateway).
For now, continue using the current page and event submission process (freeze period dates to be advised).

If you have any questions, please contact halo@digital.ox.ac.uk

Characterisation of alloantigens and their cognate T cell responses in Acute Myeloid Leukaemia. Implications For A Novel Approach To TCR Therapy

Paresh Vyas is a clinical academic and Deputy Director of the MRC Molecular Haematology Unit (MHU), Weatherall Institute of Molecular Medicine (WIMM) at the University of Oxford. He is clinical lead for AML (Acute Myeloid Leukaemia) and MDS (Myelodysplasia) for Oxford and leads Phase I-III clinical trials in the UK and international in AMl and MDS. His research focuses on allo-immune responses to leukemia and the molecular and cellular biology of normal and leukaemic haemopoiesis.

Date: 28 March 2023, 9:30
Venue:
Wellcome Trust Centre for Human Genetics
Headington OX3 7BN
See location on maps.ox

Details: Room A&B
Speaker: Professor Paresh Vyas (University of Oxford, Weatherall Institute of Molecular Medicine)
Organising department: CAMS Oxford Institute
Organiser contact email address: coi.admin@ndm.ox.ac.uk
Hosts: Prof Tao Dong (CAMS Oxford Institute, University of Oxford), Dr Ricardo Fernandes (CAMS Oxford Institute, University of Oxford)
Part of: CAMS Oxford Institute Seminars
Booking required?: Not required
Audience: Members of the University only
This talk features in the following public collections:
- Oxford Cancer Immuno-Oncology Network
Editor: Natalie Baker